{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:55Z","timestamp":1790644495888,"version":"4.1.0"},"reference-count":70,"publisher":"Japanese Circulation Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1253\/circj.cj-15-1326","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T17:08:01Z","timestamp":1456420081000},"page":"913-923","source":"Crossref","is-referenced-by-count":42,"title":["Prognostic Value of Prothrombin Time International Normalized Ratio in Acute Decompensated Heart Failure\u3000\u2013 A Combined Marker of Hepatic Insufficiency and Hemostatic Abnormality \u2013"],"prefix":"10.1253","volume":"80","author":[{"given":"Atsushi","family":"Okada","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Sugano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Takashio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Aiba","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo F.","family":"Kusano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the NaDEF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state?: Virchow\u2019s triad revisited. <i>J Am Coll Cardiol<\/i> 1999; 33: 1424\u20131426."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. <i>N Engl J Med<\/i> 1997; 336: 251\u2013257.","DOI":"10.1056\/NEJM199701233360403"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. <i>Eur Heart J<\/i> 1993; 14: 205\u2013212.","DOI":"10.1093\/eurheartj\/14.2.205"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1995; 25: 1634\u20131640.","DOI":"10.1016\/0735-1097(95)00049-A"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: Role of oral anticoagulants and successful heart transplantation. <i>Br J Haematol<\/i> 2004; 126: 85\u201392.","DOI":"10.1111\/j.1365-2141.2004.04977.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wang IW, Kottke-Marchant K, Vargo RL, McCarthy PM. Hemostatic profiles of HeartMate ventricular assist device recipients. <i>ASAIO J<\/i> 1995; 41: M782\u2013M787.","DOI":"10.1097\/00002480-199507000-00120"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kaplon RJ, Gillinov AM, Smedira NG, Kottke-Marchant K, Wang IW, Goormastic M, et al. Vitamin K reduces bleeding in left ventricular assist device recipients. <i>J Heart Lung Transplant<\/i> 1999; 18: 346\u2013350.","DOI":"10.1016\/S1053-2498(98)00066-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jafri SM. Hypercoagulability in heart failure. <i>Semin Thromb Hemost<\/i> 1997; 23: 543\u2013545.","DOI":"10.1055\/s-2007-996133"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. de Peuter OR, Kok WE, Torp-Pedersen C, Buller HR, Kamphuisen PW. Systolic heart failure: A prothrombotic state. <i>Semin Thromb Hemost<\/i> 2009; 35: 497\u2013504.","DOI":"10.1055\/s-0029-1234145"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. <i>Am Heart J<\/i> 1994; 127: 607\u2013612.","DOI":"10.1016\/0002-8703(94)90670-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sechi LA, Novello M, Colussi G, Di Fabio A, Chiuch A, Nadalini E, et al. Relationship of plasma renin with a prothrombotic state in hypertension: Relevance for organ damage. <i>Am J Hypertens<\/i> 2008; 21: 1347\u20131353.","DOI":"10.1038\/ajh.2008.293"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Marcucci R, Gori AM, Giannotti F, Baldi M, Verdiani V, Del Pace S, et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. <i>J Thromb Haemost<\/i> 2006; 4: 1017\u20131022.","DOI":"10.1111\/j.1538-7836.2006.01916.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Anzai T, Yoshikawa T, Kaneko H, Maekawa Y, Iwanaga S, Asakura Y, et al. Association between serum C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction. <i>Chest<\/i> 2004; 125: 384\u2013389.","DOI":"10.1378\/chest.125.2.384"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: Relationship to treatment and prognosis. <i>Blood Coagul Fibrinolysis<\/i> 2003; 14: 515\u2013521.","DOI":"10.1097\/00001721-200309000-00001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. <i>Eur J Clin Invest<\/i> 2003; 33: 941\u2013948.","DOI":"10.1046\/j.1365-2362.2003.01252.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. <i>Circulation<\/i> 2004; 109: 2698\u20132704.","DOI":"10.1161\/01.CIR.0000131660.51520.9A"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chong AY, Lip GY. Viewpoint: The prothrombotic state in heart failure: A maladaptive inflammatory response? <i>Eur J Heart Fail<\/i> 2007; 9: 124\u2013128.","DOI":"10.1016\/j.ejheart.2006.05.009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. <i>Circulation<\/i> 2003; 108: 512\u2013515.","DOI":"10.1161\/01.CIR.0000085568.13915.1E"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. <i>Circulation<\/i> 2003; 107: 398\u2013404.","DOI":"10.1161\/01.CIR.0000052617.91920.FD"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. <i>J Am Coll Cardiol<\/i> 2004; 43: 2075\u20132082.","DOI":"10.1016\/j.jacc.2003.11.062"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Davis CJ, Gurbel PA, Gattis WA, Fuzaylov SY, Nair GV, O\u2019Connor CM, et al. Hemostatic abnormalities in patients with congestive heart failure: Diagnostic significance and clinical challenge. <i>Int J Cardiol<\/i> 2000; 75: 15\u201321.","DOI":"10.1016\/S0167-5273(00)00300-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Alehagen U, Dahlstrom U, Lindahl TL. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. <i>Thromb Haemost<\/i> 2004; 92: 1250\u20131258.","DOI":"10.1160\/TH04-05-0278"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Jug B, Vene N, Salobir BG, Sebestjen M, Sabovic M, Keber I. Prognostic impact of haemostatic derangements in chronic heart failure. <i>Thromb Haemost<\/i> 2009; 102: 314\u2013320.","DOI":"10.1160\/TH08-11-0721"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Alehagen U, Dahlstrom U, Lindahl TL. Low plasma concentrations of coagulation factors II, VII and XI indicate increased risk among elderly with symptoms of heart failure. <i>Blood Coagul Fibrinolysis<\/i> 2010; 21: 62\u201369.","DOI":"10.1097\/MBC.0b013e328332aa2b"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Marin F, Roldan V, Martinez JG, Hernandez-Madrid A, Hernandez-Romero D, Ortego M, et al. Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: A pilot study. <i>Thromb Res<\/i> 2011; 128: 391\u2013394.","DOI":"10.1016\/j.thromres.2011.05.022"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, et al. Hypoxic hepatitis: Underlying conditions and risk factors for mortality in critically ill patients. <i>Intensive Care Med<\/i> 2009; 35: 1397\u20131405.","DOI":"10.1007\/s00134-009-1508-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Raurich JM, Llompart-Pou JA, Ferreruela M, Colomar A, Molina M, Royo C, et al. Hypoxic hepatitis in critically ill patients: Incidence, etiology and risk factors for mortality. <i>J Anesth<\/i> 2011; 25: 50\u201356.","DOI":"10.1007\/s00540-010-1058-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. <i>N Engl J Med<\/i> 1971; 285: 1441\u20131446.","DOI":"10.1056\/NEJM197112232852601"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. <i>Bibl Haematol<\/i> 1983; 49: 265\u2013275.","DOI":"10.1159\/000408467"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yang JA, Kato TS, Shulman BP, Takayama H, Farr M, Jorde UP, et al. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. <i>J Heart Lung Transplant<\/i> 2012; 31: 601\u2013610.","DOI":"10.1016\/j.healun.2012.02.027"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. <i>J Am Soc Echocardiogr<\/i> 2005; 18: 1440\u20131463.","DOI":"10.1016\/j.echo.2005.10.005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. <i>J Am Soc Echocardiogr<\/i> 2003; 16: 777\u2013802.","DOI":"10.1016\/S0894-7317(03)00335-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. <i>Circ J<\/i> 2013; 77: 705\u2013711.","DOI":"10.1253\/circj.CJ-12-1091"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wheeler AP, Rice TW. Coagulopathy in critically ill patients: Part 2-soluble clotting factors and hemostatic testing. <i>Chest<\/i> 2010; 137: 185\u2013194.","DOI":"10.1378\/chest.08-2535"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. <i>Eur Heart J<\/i> 2013; 34: 742\u2013749.","DOI":"10.1093\/eurheartj\/ehs332"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ambrosy AP, Gheorghiade M, Bubenek S, Vinereanu D, Vaduganathan M, Macarie C, et al. The predictive value of transaminases at admission in patients hospitalized for heart failure: Findings from the RO-AHFS registry. <i>Eur Heart J Acute Cardiovasc Care<\/i> 2013; 2: 99\u2013108.","DOI":"10.1177\/2048872612474906"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Biegus J, Zymlinski R, Sokolski M, Nawrocka S, Siwolowski P, Szachniewicz J, et al. Liver function tests in patients with acute heart failure. <i>Pol Arch Med Wewn<\/i> 2012; 122: 471\u2013479.","DOI":"10.20452\/pamw.1413"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kinugasa Y, Kato M, Sugihara S, Hirai M, Kotani K, Ishida K, et al. A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure: Hypoalbuminemia as an additional prognostic factor. <i>Circ J<\/i> 2009; 73: 2276\u20132281.","DOI":"10.1253\/circj.CJ-09-0498"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Uthamalingam S, Kandala J, Daley M, Patvardhan E, Capodilupo R, Moore SA, et al. Serum albumin and mortality in acutely decompensated heart failure. <i>Am Heart J<\/i> 2010; 160: 1149\u20131155.","DOI":"10.1016\/j.ahj.2010.09.004"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. van Deursen VM, Edwards C, Cotter G, Davison BA, Damman K, Teerlink JR, et al. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. <i>J Card Fail<\/i> 2014; 20: 407\u2013413.","DOI":"10.1016\/j.cardfail.2014.03.003"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. <i>Eur J Heart Fail<\/i> 2012; 14: 302\u2013311.","DOI":"10.1093\/eurjhf\/hfs007"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Scholfield M, Schabath MB, Guglin M. Longitudinal trends, hemodynamic profiles, and prognostic value of abnormal liver function tests in patients with acute decompensated heart failure: An analysis of the ESCAPE trial. <i>J Card Fail<\/i> 2014; 20: 476\u2013484.","DOI":"10.1016\/j.cardfail.2014.05.001"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Shinagawa H, Inomata T, Koitabashi T, Nakano H, Takeuchi I, Naruke T, et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. <i>Circ J<\/i> 2008; 72: 364\u2013369.","DOI":"10.1253\/circj.72.364"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Vyskocilova K, Spinarova L, Spinar J, Mikusova T, Vitovec J, Malek J, et al. Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. <i>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub<\/i> 2015; 159: 429\u2013436.","DOI":"10.5507\/bp.2014.014"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Chintanaboina J, Haner MS, Sethi A, Patel N, Tanyous W, Lalos A, et al. Serum bilirubin as a prognostic marker in patients with acute decompensated heart failure. <i>Korean J Intern Med<\/i> 2013; 28: 300\u2013305.","DOI":"10.3904\/kjim.2013.28.3.300"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sato T, Yamauchi H, Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, et al. Serum cholinesterase is an important prognostic factor in chronic heart failure. <i>Heart Vessels<\/i> 2015; 30: 204\u2013210.","DOI":"10.1007\/s00380-014-0469-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. <i>J Card Fail<\/i> 2002; 8: 216\u2013224.","DOI":"10.1054\/jcaf.2002.0804216"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Liu M, Chan CP, Yan BP, Zhang Q, Lam YY, Li RJ, et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. <i>Eur J Heart Fail<\/i> 2012; 14: 39\u201344.","DOI":"10.1093\/eurjhf\/hfr154"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49. Abe S, Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y, Yamauchi H, et al. Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure. <i>PLoS One<\/i> 2014; 9: e100618, doi:10.1371\/journal.pone.0100618.","DOI":"10.1371\/journal.pone.0100618"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Inohara T, Kohsaka S, Shiraishi Y, Goda A, Sawano M, Yagawa M, et al. Prognostic impact of renal and hepatic dysfunction based on the MELD-XI score in patients with acute heart failure. <i>Int J Cardiol<\/i> 2014; 176: 571\u2013573.","DOI":"10.1016\/j.ijcard.2014.08.052"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E, et al. Hepatic dysfunction in ambulatory patients with heart failure: Application of the MELD scoring system for outcome prediction. <i>J Am Coll Cardiol<\/i> 2013; 61: 2253\u20132261.","DOI":"10.1016\/j.jacc.2012.12.056"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Gheorghiade M, Vaduganathan M, Fonarow GC, Greene SJ, Greenberg BH, Liu PP, et al. Anticoagulation in heart failure: Current status and future direction. <i>Heart Fail Rev<\/i> 2013; 18: 797\u2013813.","DOI":"10.1007\/s10741-012-9343-x"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Nakatani Y, Mizumaki K, Nishida K, Hirai T, Sakabe M, Oda Y, et al. Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients. <i>Circ J<\/i> 2012; 76: 317\u2013321.","DOI":"10.1253\/circj.CJ-11-0885"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Mahe I, Drouet L, Chassany O, Mazoyer E, Simoneau G, Knellwolf AL, et al. D-dimer: A characteristic of the coagulation state of each patient with chronic atrial fibrillation. <i>Thromb Res<\/i> 2002; 107: 1\u20136.","DOI":"10.1016\/S0049-3848(02)00184-6"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin treatment. <i>Br Heart J<\/i> 1995; 73: 527\u2013533.","DOI":"10.1136\/hrt.73.6.527"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Jafri SM, Mammen EF, Masura J, Goldstein S. Effects of warfarin on markers of hypercoagulability in patients with heart failure. <i>Am Heart J<\/i> 1997; 134: 27\u201336.","DOI":"10.1016\/S0002-8703(97)70103-0"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. <i>N Engl J Med<\/i> 2012; 366: 1859\u20131869.","DOI":"10.1056\/NEJMoa1202299"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, et al. Intracranial hemorrhage during dabigatran treatment: Case series of eight patients. <i>Circ J<\/i> 2014; 78: 1335\u20131341.","DOI":"10.1253\/circj.CJ-13-1534"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: Comparison with those during warfarin. <i>Stroke<\/i> 2014; 45: 2805\u20132807.","DOI":"10.1161\/STROKEAHA.114.006661"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. <i>Thromb Haemost<\/i> 2010; 104: 976\u2013983.","DOI":"10.1160\/TH10-04-0247"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. <i>Thromb Haemost<\/i> 2011; 105: 181\u2013189.","DOI":"10.1160\/TH10-06-0393"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. <i>J Heart Lung Transplant<\/i> 2011; 30: 218\u2013226.","DOI":"10.1016\/j.healun.2010.08.027"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2011; 365: 981\u2013992.","DOI":"10.1056\/NEJMoa1107039"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2009; 361: 1139\u20131151.","DOI":"10.1056\/NEJMoa0905561"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Esmon CT. Targeting factor Xa and thrombin: Impact on coagulation and beyond. <i>Thromb Haemost<\/i> 2014; 111: 625\u2013633.","DOI":"10.1160\/TH13-09-0730"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Spronk HM, de Jong AM, Crijns HJ, Schotten U, Van Gelder IC, Ten Cate H. Pleiotropic effects of factor Xa and thrombin: What to expect from novel anticoagulants. <i>Cardiovasc Res<\/i> 2014; 101: 344\u2013351.","DOI":"10.1093\/cvr\/cvt343"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. <i>Thromb Haemost<\/i> 2008; 100: 101\u2013109.","DOI":"10.1160\/TH08-02-0127"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. <i>Mediators Inflamm<\/i> 2011; 2011: 432080.","DOI":"10.1155\/2011\/432080"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. <i>Atherosclerosis<\/i> 2015; 242: 639\u2013646.","DOI":"10.1016\/j.atherosclerosis.2015.03.023"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Zuo P, Zhou Q, Zuo Z, Wang X, Chen L, Ma G. Effects of the factor Xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein E-deficient mice. <i>Circ J<\/i> 2015; 79: 2499\u20132508.","DOI":"10.1253\/circj.CJ-15-0285"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/4\/80_CJ-15-1326\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T20:43:25Z","timestamp":1567629805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/4\/80_CJ-15-1326\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-15-1326","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}